Cartesian Therapeutics, Inc.

Cartesian Therapeutics (RNAC) reported one officer departure via 8-K filing on May 26, 2026—a material corporate event that warrants context around timing, role criticality, and succession planning. Our 90-day scan detected no cyber incidents, but a single officer exit can signal internal instability or strategic shifts that equity holders need to understand. The full $49 Report adds our dilution risk score, detailed 8-K narrative analysis, 12-month financing history, and AI-flagged risk signals that contextualize whether this departure is routine or symptomatic of deeper challenges.